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Review 
The term "scleroderma" traditionally has been 
uti l ized to describe the cutaneous changes of a 
heterogeneous group of disorders involving hardening, 
tightening, and decreased elasticity of the skin.' Two 
extreme forms have been identified-localized and 
diffuse. 
The localized form, specifically morphea, i s  charac- 
terized by well-circumscribed, sclerotic plaques with an 
ivory-colored center and a surrounding violaceous halo. 
The violaceous halo implies active disease. Visceral in- 
volvement is  not observed and, therefore, prognosis is  
generally favorable.2 
In sharp contrast is the diffuse type, or progressive 
systemic sclerosis (PSS), which is correlated with wide- 
spread sclerosis, Raynaud's phenomenon, and multi- 
system invol~ement .~-~ Prognosis is poor, with death 
often secondary to renal failure or pulmonary fibrosis5 
Between these two extremes are intermediate forms, 
with generalized morphea representing a form of 
localized scleroderma and acrosclerosis and the CREST 
syndrome representing a form of PSS.1.6 
Formulating a definition of the full spectrum of PSS 
necessitates an understanding of the etiology and patho- 
genesis. This, in turn, may clarify the interrelationship 
between progressive systemic sclerosis, morphea, and 
the intermediate varieties. 
According to Lever and Schaumberg-Lever, histologic 
differentiation of the skin lesions in morphea versus PSS 
i s  usually impossible; however, they identify two stages: 
(1 1 early inflammatory; and (2 )  !ate sclerotic.' During the 
early inflammatory stage, the dermis reveals closely 
packed, thick collagen bundles in conjunction with a 
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mild, predominantly lymphocytic, inflammatory infil- 
trate that is located in the perivascular spaces and be- 
tween the collagen bundles. This infiltrate appears to be 
much more pronounced in its distribution in the subcu- 
taneous tissue and is accompanied by deposition of new 
collagen in these areas. In the late sclerotic stage, the 
inf lam matory i nfi It rate almost corn pletel y disappears, 
with concurrent replacement of the subcutaneous tissue 
by collagen. 
Three predominant theories have emerged in the in- 
vestigation of the pathogenesis of PSS. The first theory 
advocates evolution of the primary lesion within the 
blood vessel.8 The second postulates an autoimmune 
basis for the di~ease.~ The third considers the primary 
event an abnormality of collagen metabolism, man- 
ifested by fibr0sis.j 
The true pathogenesis of PSS is essentially unknown at 
present. The separation of these theories is  artificial and 
merely facilitates the discussion of pathogenesis. One 
may speculate that the three theories, rather than exist- 
ing independently, might be somehow interdependent 
and interrelated. 
The Vascular Theory 
The vascular manifestations of PSS include its early 
edematous phase, Raynaud's phenomenon, telangiec- 
tasias, capillary abnormalities detectable through both 
nailfold and ultrastructural microscopy, and widespread 
multisystem vascular disease.1° The most striking his- 
tologic abnormalities occur in the small blood vessels- 
the small arteries, arterioles, and capillaries-with occa- 
sional involvement of the major arteries.".12 The pri- 
mary vascular lesion i s  believed to be manifest by a 
distinctive intimal proliferation, with cells arranged con- 
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centrically in a matrix of ground s~bstance.’~ This pat- 
tern i s  referred to as fibromucinous endothelial 
change.’” 
Recent electron microscopic studies by Fleischmajer 
and Perlish14 reveal the earliest change in PSS capillaries 
to be large gaps between endothelial cells. These re- 
searchers hypothesize that the gaps would allow extra- 
vasation of plasma fluids into the extracellular matrix, 
thereby creating the early edematous features of the dis- 
ease that precede the characteristic fibrotic phase. They 
also document that after development of these endothe- 
lial cell gaps, cells undergo swelling and subsequent 
destruction, with release of organelles into the lumen. 
Capillary obstruction frequently results. This repeated 
pattern of endothelial cell destruction i s  believed re- 
sponsible for the observed replication of the basal 
laminae,14 with each basal lamina layer corresponding 
to the residual of one endothelial cell regeneration.’j 
What, then, i s  the etiology of the actual endothelial 
cell destruction? Could ischemia be implicated? It is 
known that Raynaud‘s phenomenon is  often the present- 
ing sign of PSS and that endothelial cell damage may 
occur in response to hypoxia.I6 In addition, Kristensen 
and Henriksenl5 report decreased compliance of extra- 
vascular tissue in PSS. Diminished circulation, which 
may occur as a result of this decreased compliance, may 
also contribute to hypoxia.17 Kahaleh et al lo have dem- 
onstrated the existence of an endothelial cell-specific 
cytotoxic factor, demonstrating its occurrence in 31 of 
52 patients with PSS. The factor i s  characterized as 
heat-stable, nondialyzable, and able to migrate with al- 
bumin on gel filtration. 
Vibrational energy also has been associated with en- 
dothelial cell damage. People who work with vibrating 
tools have been known to develop scleroderma-like 
c hanges.ls, Is 
In addition to these ongoing destructive processes, 
some vessels exhibit discrete areas in which endothelial 
cells remain intact, with their nuclei in prophaseFO in 
vitro autoradiography with 3H-thymidine demonstrates a 
marked increase in endothelial and pericyte cell labeling 
in these areas.2O The significant decrease in the number 
of capillaires observed in the papillary layer of PSS pa- 
tients may be the result of an overwhelming predomi- 
nance of endothelial cell destruction, rather than 
pr01iferation.I~ 
Why does proliferation occur at all? Fleischmajer et 
alZO offer several interpretations. Proliferation may sim- 
ply be a reparative process in response to endothelial 
cell destruction. What is detected as proliferation may 
actually be a measure of the differentiation of endothe- 
lial cells into fibroblast or fibroblast-like cells. Or, en- 
dothelial cell proliferation may produce enlargement of 
existing capillaries with resultant telangiectasias. 
In this context, it i s  interesting to note that the telangi- 
ectasias observed in PSS usually occur in sites where 
Raynaud’s phenomenon ha5 been documented-the 
face, tongue, lips, upper chest, and hands.2I It may there- 
fore be valid to hypothesize that ischemia triggers 
endothelial cell destruction, which in turn stimulates a 
reparative process responsible for endothelial cell pro- 
liferation, with subsequent telangiectasia formation. 
Changes in the microvasculature in PSS as well as in 
other connective tissue diseases have been investigated 
by Maricq et a1,22 who employed the technique of wide- 
field capillary microscopy. Applied to PSS patients, this 
technique has uncovered a distinctive microvasculature 
pattern consisting of dilated and distorted capillary loops 
alternating with avascular areas. Additionally, these au- 
thors have found a positive correlation between the de- 
gree and extent of abnormal microvasculature patterns 
and the scope of multisystem involvement. 
A perivascular cellular infiltrate has been associated 
with the above-mentioned vascular changes.*O This infil- 
trate comprises lymphocytes, plasma cells, macro- 
phages, and monocytes. The causative mechanism for 
this cellular response is  unknown at present. 
The observed perivascular fibrosis may be secondary 
to the proliferating endothelial cells, pericytes, or peri- 
vascular fibroblasts, all of which reveal a prominent 
rough endoplasmic reticulum on electron microscopic 
examination suggesting that these cells may be impli- 
cated in increased collagen synthesis.2o 
Abnormal responsiveness of the blood vessels of PSS 
patients to catecholamines and serotonin has also been 
scrutinized, with conflicting r e s ~ l t s . ~ ~ - ~ ~  
The Immune Theory 
It has been proposed that PSS may be of autoimmune 
etiology because of the immunologic abnormalities that 
are observed along with the presence of cellular infil- 
trates composed of lymphocytes, plasma cells, and 
macro phage^.^' This theory i s  further supported by the 
association of PSS with other diseases of possible auto- 
immune etiology, such as Hashimoto’s thyroiditis, Sjo- 
gren’s syndrome, systemic lupus erythematosis (SLE), 
dematomyositis, biliary cirrhosis, and MCTD.32-39 
Although the number of circulating 6 lymphocytes has 
been found to be norrna1,35 serum protein electro- 
phoresis reveals a polyclonal gammopathy in one-half of 
PSS patients?6 Approximately one-half of patients have 
a positive test for antinuclear antibodies?? Antibody to 
Scl-70 antigen, antibody to centromere, and antinucleo- 
lar antibody are highly specific for PSS.4O The anticen- 
tromere antibody appears to be highly selective for the 
CREST variant of PSS. This antibody occurs in approxi- 
mately 57% of patients with the CREST syndrome, com- 
pared with approximately 8% in patients with PSS. 
Twenty to thirty percent of patients exhibit low titers of 
rheumatoid factor? Sixty-six percent of patients have 
anti-smooth-muscle antibody?8 Five percent have pos- 
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itive LE test results but show a negative direct immuno- 
fluorescence in contrast to SLE.4I N-DNA antibodies and 
cryofibrinogen are also p r e ~ e n t . ~ ~ . ~ ~  Immune complexes 
and complement deposition have been demonstrated in 
the glomeruli and intralobular arteries of the scleroder- 
matous kidneyA4 Antibodies directed against interstitial 
(Type I )  and basement membrane (Type IV) collagens in 
the sera of patients with PSS also have been observed4j 
(Table 1). 
recently reported a decrease in the 
number of circulating T cells in patients with PSS. Utiliz- 
ing antisera specific for B and T cells, it has been demon- 
strated that T lymphocytes comprise the majority of the 
lymphocytic infiltrate seen in the dermis and the sub- 
cutaneous tissue during the inflammatory stage.47 The 
reduction in the number of circulating T cells has been 
correlated with the magnitude of visceral involvement: 
patients with lower T cell counts show more extensive 
disease.46 Kondo et a147 found that lymphocytes of PSS 
patients respond to extracts of both normal and 
sclerodermatous skin in the migration inhibition assay, 
implying that the lymphocytes are sensitized to a 
cutaneous antigen present in these patients. Because of 
the crude extracts they used, however, it was impossible 
to ascertain the exact nature of this antigen from the 
study. Johnson and Ziff48 documented that in vitro stimu- 
lation of lymphocytes by phytohemagglutinin resulted in 
the release of a lymphokine. This, in turn, stimulates 
production of collagen by fibroblasts. This lymphokine, 
which is  nondialyzable and stable at -70 C, may be the 
basis of lymphocyte-fibroblast interaction in PSS. 
Although several functional studies of the immune sys- 
tem have been ~ n d e r t a k e n , l ~ - ~ ~  results to date are in- 
conclusive. The major drawback in the autoimmune 
hypothesis lies in the lack of correlation between im- 
mune alterations and the duration of the disease, the 
clinical severity of the disease, and the presence of cellu- 
lar infiltrates in the skin.jO 
Perhaps an understanding of these immune alterations 
and even the pathogenesis of PSS will be discovered in 
the principles of the graft-versus-host (GVH) reaction. 
There are three theoretic requirements for the GVH 
reaction to occur: ( 1 )  the graft must consist of foreign, 
lymphoid, immunocompetent cells in sufficient quan- 
tities; (2) the host must be in a state of immunologic 
compromise; and (3) there must be histocompatability 
differences between the host and the graft.jl 
GVH has been separated into acute and chronic 
The late chronic phase involves cutaneous 
alterations that are indistinguishable both clinically and 
histologically from scleroderma. The current literature 
implicates both humoral and cell-mediated mechanisms 
in GVH path0genesis.j' What makes GVH disease so 
exciting is  that, for the first time, we have an experimen- 
tal human or animal model to study the pathogenetic 
mechanisms involved in scleroderma. One may there- 
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TABLE 1 .  Serologic Abnormalities 
in Progressive Systemic Sclerosis 
Polyclonal gammopathy 
ANA-Scl-70, centromere, nucleolar 
Rheumatoid factor 
Anti-smooth-muscle antibody 
Positive LE test result 
N-DNA antibodies 
Cryofibrinogen 
fore speculate that unraveling the complexities of the 
GVH reaction may lead to a clearer concept of the 
pathogenesis of PSS. 
Abnormality of Collagen Metabolism Theory 
Clinically, the most striking feature of PSS is  the thick- 
ening and severe rigidity of the skin. Because the struc- 
tural stability of the skin i s  almost totally dependent 
upon the fibrous protein collagen, qualitative and quan- 
titative changes in collagen could conceivably lead to 
the signs and symptoms observed in PSS." This concept 
has led the way for a vast amount of research concerning 
collagen and its role in the pathogenesis of PSS. 
In PSS, fat i s  replaced by collagen both in the subcu- 
taneous tissue and in tissue surrounding the eccrine 
sweat glands.j5 Fleischmajer points out that at light-mi- 
croscopic examination, the dermis exhibits compact 
connective tissue due to a reduction in the interfascicu- 
lar spaces. Additionally, collagen in these areas is  com- 
posed of thick bundles that stain normally with trichome 
stains.j This i s  in contrast to the hyalinized connective 
tissue of the subcutaneous fat, which consists of fine 
fibers and stains lightly with trichome stains. 
At electron-microscopic examination, the upper der- 
mis reveals thick aggregates of collagen fibrils. Nor- 
mally, these fibrils have a diameter of 900-1 100 A and a 
periodicity of 640 A. In the lower dermis and subcu- 
taneous tissue, there are large areas of fine collagen fi- 
brils 200-400 A in diameter with normal periodicity.56 
Areas with bimodal distribution are also present, in 
which fibri l diameter is  350-950 A.j5 In the fat 
trabeculae, in addition to fibrils 200-400 A in diameter, 
there occur well-circumscribed regions of fibrils 100 A 
in diameter without discernable peri0dicity.j Therefore, 
one may observe areas in the upper dermis that appear 
to be composed of normal, mature collagen, whereas 
the lower dermis and subcutaneous tissue are replaced 
by what appears to be immature collagen. 
Experimentally, it has been demonstrated that a high 
3H-proline uptake occurs by the large numbers of fibro- 
blast-like cells in the hyalinized areas of the subcu- 
taneous tissue.z0 Correlation of this finding with the 
electron-microscopic findings imply that subcutaneous 
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tiswe fibroblasts are engaged in collagen synthesis; 
however, this cannot be substantiated, because proline 
i s  incorporated into proteins other than ~ol lagen.~ 
Although the concentration of collagen is  normal in 
PSS,j' a net increase in collagen occurs that i s  directly 
proportional to the increase in skin This net 
increase may be due to an accelerated rate of fibroblast 
collagen synthesis.53 Findings in support of this hypothe- 
sis include: ( 1 )  an increaw in prolylhydroxylase activ- 
ity60; and (2) accelerated incorporation of radioactive 
proline and the synthesis of radioactive hydroxyproline in 
skin collagen biopsies obtained from PSS patients when 
compared with biopsies from normal controls.6' 
Another rationalization for this net increase in colla- 
gen may be that fibroblasts that assume a normal rate of 
collagen production may have defective negative feed- 
back mechanisms. They are, essentially, unable to turn 
off.62 This might account for the net increase in collagen 
despite the normal production rate. 
Perlish et al* found that fibroblasts that originate in 
involved areas undergo a rate of collagen synthesis 
equal to or less than fibroblasts isolated from adjacent, 
clinically noninvolved sites. It is  apparent that, in PSS, 
there are discrepancies concerning the rate of fibroblast 
collagen synthesis. Attempting to reconcile these dis- 
crepancies, Perlish et a1 postulated that experimental de- 
sign, ie, the culture method, may be responsible. Inves- 
tigators employing different media obtained conflicting 
results. One group of results i s  based on short-term, 24- 
hour studies, while other data are founded on long-term, 
3-day experiments. These authors speculated that 
another significant factor and experimental design vari- 
able is the site of biopsy. They postulated that the cells in 
the center of the sclerodermatous plaque might be inac- 
tive or metabolically suppressed because of their envi- 
ronment. They might be incapable of synthesizing pro- 
tein or collagen to any significant degree. In contrast, the 
cells at the lesion's periphery actively synthesize colla- 
gen, thus accounting for the increased plaque diameter 
observed in active lesions. It has also been demonstrated 
that fibroblasts obtained from the lower portions of in- 
volved dermis accumulate significantly more collagen 
than those from the upper portions."Sw The author's 
final factor responsible for experimental discrepancy in- 
volves the stage of the disease. Herbert et als4 in studying 
the biosynthesis and maturation of skin collagen in 
scleroderma, showed that collagen isolated from 
xlerodermatous skin contains reducible cross-links. 
This implies that new collagen is being deposited in the 
skin; however, the absence of reducible cross-links in 
the center of the older plaques and from patients with 
inactive disease implies that no new collagen is being 
deposited. 
proposed two distinct fibroblast populations in PSS. The 
first is trapped within the collagen matrix of the lesion 
On the basis of the above information, Perlish et 
and is consequently metabolically inactive. The second 
i s  composed of cells located in the periphery as well as 
underlying the lesion. These fibroblasts actively synth- 
esize collagen but may be similar metabolically to fibro- 
blasts within the normal population. In addition, Fleisch- 
majer et recently reported great heterogeneity 
among scleroderma fibroblasts regarding collagen 
synthesis. 
A decrease in the concentration of collagenase also 
may cause a net increase in collagen. This decrease has 
been confirmed by some authors but rejected by 
others.66 
The net increase in collagen may be a result of: ( 1 )  an 
increase in the rate of fibroblast collagen synthesis; (2) a 
normal rate of collagen synthesis but defective regula- 
tory mechanisms; (3)  increased fibroblast proliferation at 
the site as reflected in increased endothelial cell label- 
ing; and/or (4) a decrease in the concentration of 
collagenase. 
Conclusion 
There are numerous theories on the pathogenesis of 
PSS. At present, no unifying hypothesis can satisfactorily 
explain all of the abnormalities observed in the disease. 
Perhaps in the future, a clearer understanding of the 
etiology and pathogenesis of progressive systemic 
sclerosis will emerge. 
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